Turning employee sentiment into hard operational data

Tern plc

Standard wellbeing programmes rarely solve the problems that matter. They tend to be broad, reactive, and detached from how a business actually runs. Managers see participation figures or survey responses and assume all is well.

That gap is now being addressed by tools built leadership decision-making. Instead of asking employees to rate how they feel, these tools extract meaning from how people actually speak, in comments, conversations and open-ended feedback.

Talking Medicines is one of the companies leading this shift. Its PeopleVoice platform translates employee language into operational insight. If a team is struggling with direction or motivation, it shows up early, before it hits output. It’s quantifiable risk data, broken down by cohort, trend and theme. And that data can be used to act precisely, not generally.

The strongest use cases are emerging in teams with high turnover or shifting targets. Instead of issuing another pulse survey or resilience webinar, leaders can see which roles are losing clarity, where communication is falling apart, or which functions are beginning to disengage.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search